98%
921
2 minutes
20
A new library of flavone derivatives targeting two active sites of monoamine oxidases ("aromatic cage" and substrate cavity) were designed and synthesized using click chemistry (CuAAC reaction) between 6-N -2-phenyl chromones (Az1-Az2) and a series of alkynes (k1-k20). Their inhibitory activities against MAO isoforms (MAO-A and MAO-B) are evaluated. Compounds with fluorine, amide bonds, or amino bonds have shown better inhibition. The most potent flavone MAO inhibitor studied is Az2k19 (1.6 μm for MAO-A, 2.1 μm for MAO-B), while Az1k15 and Az2k15 displayed better selectivity toward MAO-B (SI > 10). Docking studies are in accordance with our hypothesis that these inhibitors are most likely located at both the substrate cavity and the "aromatic cage". Our results show that it is considerable to develop new MAO inhibitors from C6 substitution of flavone derivatives and that these compounds are also potential for the treatment of diseases associated with MAOs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/cbdd.12841 | DOI Listing |
Bioorg Chem
August 2025
Key Lab of Protein Structure and Function of Universities in Hunan Province, University of South China, Hengyang, Hunan 421001, China; School of Chemistry and Chemical Engineering, University of South China, Hengyang, Hunan 421001, China. Electronic address:
Inhibition of human monoamine oxidase B (hMAO-B) to prevent both oxidative stress and lipid metabolism disorders, which are high-risk factors for pathogenesis of atherosclerosis, is a potential strategy for the treatment of atherosclerosis. In this study, we have explored a series of C-3 nitrothiophene substituted thiochromone analogues that showed good to excellent potency against hMAO-B. The strategy of introduction the nitro-group into thiophene linker, which contributes pivotal interactions with Cys172, significantly improved the potency and selectivity of these compounds.
View Article and Find Full Text PDFMol Cell
August 2025
Lingang Laboratory, Shanghai 200031, China. Electronic address:
YAP/TAZ are transcriptional co-activators that pair with transcription factor TEA/ATTS domains (TEADs) for modulating the Hippo pathway. Previous works propose the potential role of YAP/TAZ phase separation for transcriptional activation, yet the biomolecular basis of endogenous YAP/TAZ-TEAD condensates remains unclear. Here, we dissect their endogenous morphology, revealing that YAP/TAZ are client proteins recruited to TEAD condensates in various human cell lines.
View Article and Find Full Text PDFEcotoxicol Environ Saf
September 2025
Department of Cancer Diagnosis and Treatment Center, Affiliated Hospital of Jiangnan University, Wuxi 214122, China; Laboratory of Oncology Precision Diagnosis and Treatment, Wuxi Medical College of Jiangnan University, Wuxi 214122, China. Electronic address:
Colorectal cancer (CRC) is characterised by microbial dysbiosis. Trimethylamine (TMA) and trimethylamine-N-oxide (TMAO) are gut microbiota-derived metabolites produced from dietary precursors that are implicated in CRC progression. However, the underlying mechanisms by which TMA or TMAO affect CRC progression remain largely unexplored.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Zhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
Background: Accurate prognostic prediction is crucial for personalized treatment of patients with lung adenocarcinoma (LUAD) receiving epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This study aims to develop and validate a pathomics-based prognostic model for EGFR-TKI-treated patients with LUAD.
Patients And Methods: Data from 122 patients with LUAD who underwent first-line EGFR-TKI therapy were retrospectively analyzed.
Cureus
August 2025
Pulmonary and Critical Care Medicine, HCA Houston Healthcare Kingwood/University of Houston, Kingwood, USA.
Pulmonary toxicity is a serious yet frequently under-recognized complication of antidepressant therapy. With the continued rise in prescriptions, awareness of potential respiratory adverse effects is crucial. This review outlines documented cases of lung injury linked to various antidepressant classes, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, serotonin modulators, tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs).
View Article and Find Full Text PDF